Natera, Inc. - Common Stock (OQ:NTRA)

Nov 08, 2024 09:00 am ET
Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December.
Nov 01, 2024 09:00 am ET
Natera to Report its Third Quarter 2024 Results on November 12, 2024
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Oct 22, 2024 09:00 am ET
Natera to Present New Renasight Data at ASN Kidney Week 2024
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (c
Sep 16, 2024 05:17 am ET
 Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the simultaneous publication of three peer-reviewed papers, crossing a milestone of more than 85 peer-reviewed publications on Signatera. This includes:
Sep 14, 2024 02:16 pm ET
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is one of the largest and most comprehensive prospective studies of circ
Sep 08, 2024 08:22 pm ET
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain.
Aug 28, 2024 09:00 am ET
Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4 at 2:35 pm ET | 11:35 am PT in New York City.
Aug 08, 2024 04:05 pm ET
Natera Reports Second Quarter 2024 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024.
Aug 06, 2024 09:00 am ET
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA.
Jul 30, 2024 04:05 pm ET
Natera to Report its Second Quarter 2024 Results on August 8, 2024
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Jul 26, 2024 08:00 am ET
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found
Jun 03, 2024 08:00 am ET
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET).
May 23, 2024 07:30 am ET
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024.
May 14, 2024 09:00 pm ET
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Natera, Inc. (NASDAQ: NTRA) on behalf of long-term stockholders following a class action complaint that was filed against...
May 09, 2024 04:05 pm ET
Natera Reports First Quarter 2024 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.
May 03, 2024 08:00 am ET
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be
Apr 05, 2024 07:00 am ET
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’
Apr 01, 2024 08:00 am ET
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 (
Mar 18, 2024 07:00 am ET
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease (MRD)-guided adjuvant
Mar 12, 2024 08:00 am ET
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024.
Feb 29, 2024 08:00 am ET
Natera to Participate in March Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March.
Feb 28, 2024 04:05 pm ET
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023.
Feb 27, 2024 08:00 am ET
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the next phase of proceedings in its patent infringement litigation against CareDx. The U.S. District Court for the District of Delaware will now determine if CareDx owes a royalty for future infringement related to ongoing and future AlloSure testing occurring after
Feb 26, 2024 07:00 am ET
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in two new indications: ovarian cancer in the adjuvant and surveillance settings, and breast cancer in the neoadjuvant setting.
Feb 20, 2024 08:00 am ET
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Feb 05, 2024 08:00 am ET
New Study Validates Signatera™ in Endometrial Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in endometrial cancer. The full study can be found
Jan 30, 2024 09:15 am ET
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will continue to grow in the next several years. Multiple myeloma is a type of plasma cell cancer. Normal plasma cells are recognized as an important...
Jan 30, 2024 07:00 am ET
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to risk stratify and detect recurrence early in patients with rese
Jan 29, 2024 07:00 am ET
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement
Jan 25, 2024 07:00 am ET
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™
Jan 22, 2024 07:00 am ET
Natera Acquires Reproductive Health Assets from Invitae
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetics company, certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business.
Jan 22, 2024 06:00 am ET
Invitae Completes Sale of Reproductive Health Assets to Natera
SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA). 
Jan 18, 2024 08:00 am ET
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 18 – 20, 2024 in San Francis
Jan 16, 2024 05:17 pm ET
Natera Provides Update on Ravgen Trial
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury has reached a verdict in the United States District Court for the Western District of Texas regarding a patent infringement lawsuit brought by Ravgen, Inc. against Natera.
Jan 09, 2024 07:00 am ET
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following:
Dec 29, 2023 08:00 am ET
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a presentation and host a Q&A with the investment community at the c
Dec 27, 2023 11:48 pm ET
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc. (“NeoGenomics”).
Dec 26, 2023 09:00 pm ET
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Natera, Inc. (NASDAQ: NTRA) on behalf of long-term stockholders following a class action complaint that was filed against Natera on March 10, 2022 with a Class Period from February 26, 2020 to April 19, 2022. Our investigation concerns whether the board of directors of Natera have breached their fiduciary duties to the company.
Dec 21, 2023 08:00 am ET
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-info
Dec 11, 2023 12:50 pm ET
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.
Dec 06, 2023 08:30 am ET
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
Nov 14, 2023 08:00 am ET
Natera Announces Real-World Data Collaboration with Merck
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.
Nov 08, 2023 04:05 pm ET
Natera Reports Third Quarter 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023.
Nov 08, 2023 09:10 am ET
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG). This international, multi-center, randomized, phase III clinical trial is being conducted by the Europea
Nov 07, 2023 08:30 am ET
Natera to Participate in November Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.
Nov 03, 2023 10:50 pm ET
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
Oct 23, 2023 12:18 pm ET
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Natera, Inc.’s Directors and Officers for Breach of Fiduciary Duties – NTRA
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Natera, Inc. (“Natera”) (NASDAQ: NTRA) breached their fiduciary duties to...
Oct 22, 2023 01:00 pm ET
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the ability of the Signatera™ molecular residual disease (MRD) test to help identify patients with resectable colorectal cancer (CRC) who are at an increased risk of recurrence and predict
Oct 20, 2023 10:50 pm ET
NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
NEW ORLEANS, Oct. 20, 2023 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
Oct 20, 2023 09:00 am ET
Natera to Report its Third Quarter 2023 Results on November 8
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2023, after the market close on Nov. 8, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Oct 19, 2023 09:00 am ET
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare.
Oct 16, 2023 09:00 am ET
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 European Society for Medical Oncology (ESMO) Congress, taking place Oct. 20-24 in Madrid, Spain.
Oct 06, 2023 02:40 pm ET
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
Oct 04, 2023 09:00 am ET
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to detect progression early, with high sensitivity and specificity, and risk stratify patients
Oct 02, 2023 09:00 am ET
Natera Submits First PMA Module to the FDA for Signatera™
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, as a companion diagnostic (CDx) assay for patien
Sep 18, 2023 09:00 am ET
Natera Announces Senior Leadership Appointments
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.
Sep 14, 2023 09:00 am ET
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast canc
Sep 07, 2023 12:09 am ET
Natera Announces Pricing of $250 Million Follow-On Offering
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 682,500 shares of its common stock at the public offering price less the underwriting discounts and commissions.
Sep 06, 2023 04:24 pm ET
Natera Launches Proposed Follow-On Offering
Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions.
Sep 01, 2023 09:00 am ET
Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
Aug 03, 2023 04:05 pm ET
Natera Reports Second Quarter 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023.
Aug 02, 2023 04:05 pm ET
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA.
Jul 31, 2023 01:39 pm ET
Natera Files Patent Infringement Suit Against NeoGenomics
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual disease assay.
Jul 28, 2023 09:00 am ET
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility
Jul 27, 2023 08:00 am ET
Natera to Report its Second Quarter 2023 Results on August 3rd
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Jul 17, 2023 04:47 pm ET
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware issued a decision in favor of Natera in the false advertising case brought by
Jun 06, 2023 08:30 am ET
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA.
May 30, 2023 08:30 am ET
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 – 6, 2023. Signatera and Natera’s circulating tumor DNA
May 15, 2023 01:48 pm ET
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement
May 09, 2023 04:05 pm ET
Natera Reports First Quarter 2023 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023.
May 08, 2023 08:00 am ET
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer p
May 02, 2023 08:00 am ET
Natera Announces First Quarter 2023 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Apr 14, 2023 08:00 am ET
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American Association for Cancer Research (AACR) taking place April 14 – 19, 2023.
Mar 22, 2023 08:00 am ET
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in
Mar 02, 2023 07:00 am ET
Natera Announces Commercial Payor Coverage for Signatera™
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA te
Feb 28, 2023 04:05 pm ET
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook.
Feb 24, 2023 08:00 am ET
Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
Feb 21, 2023 08:00 am ET
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Feb 16, 2023 08:00 am ET
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) that Natera’s Signatera molecular residual disease (MRD) test has met coverage requirements for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer. The coverage applies across all subtypes of the disease, including hormone receptor (HR)-positive, HER2-positive, and triple negative breast cancers. This decision adds to Medicare’s p
Feb 13, 2023 09:28 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Natera, Inc. (NTRA) and Encourages Long-Term NTRA Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Natera, Inc. (NASDAQ: NTRA) on behalf of the company’s long-term investors. Recently a securities fraud complaint was filed against Natera on behalf of certain investors who purchased shares of...
Feb 02, 2023 08:01 am ET
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found
Jan 19, 2023 08:02 am ET
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San
Jan 17, 2023 08:01 am ET
Jan 03, 2023 04:05 pm ET
Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 at 9:45 a.m. PT (12:45 p.m. ET).
Dec 09, 2022 07:33 am ET
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers
Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis
Dec 07, 2022 07:33 am ET
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
AUSTIN, Texas, Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
Dec 06, 2022 04:31 am ET
Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT
Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights unique capabilities of Panorama SNP-based NIPT
Nov 23, 2022 07:33 am ET
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m. ET).
Nov 21, 2022 07:33 am ET
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
ctDNA reduction at week nine in patients treated with tebentafusp was associated with improved overall survival
Nov 19, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of Natera, Inc. (NASDAQ: NTRA), Butterfly Network, Inc. (NYSE: BFLY), Pulse Biosciences, Inc. (NASDAQ: PLSE), and SunPower Corporation (NASDAQ: SPWR)
Natera, Inc. (NASDAQ: NTRA) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Natera alleging that Defendants misrepresented and/or failed to disclose that: (i) the Company’s Panorama Non-Invasive...
Nov 15, 2022 10:01 pm ET
Natera Announces Pricing of Follow-On Offering
AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,714,500 shares of its common stock at the public offering price less the underwriting discounts and commissions.
Nov 15, 2022 03:30 pm ET
Natera Launches Proposed Follow-On Offering
AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $52,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be complet
Nov 08, 2022 03:05 pm ET
Natera Reports Third Quarter 2022 Financial Results
AUSTIN, Texas, Nov. 8, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022.
Nov 02, 2022 08:33 am ET
Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs
AUSTIN, Texas, Nov. 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective Sept. 15, 2022, with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, to provide minimal residual disease (MRD) and monitoring services with the company's personalized and tumor-informed MRD test, Signatera™.
Nov 01, 2022 11:00 am ET
Natera to Participate in Credit Suisse 31st Annual Healthcare Conference
AUSTIN, Texas, Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9 at 10:25 a.m. PT (1:25 p.m. ET).
Nov 01, 2022 08:30 am ET
Natera to Report its Third Quarter 2022 Results on November 8th
AUSTIN, Texas, Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third quarter ended September 30, 2022, after the market closes on November 8, 2022. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Oct 06, 2022 08:33 am ET
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of recurrence
Oct 04, 2022 08:33 am ET
Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection
AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta study in Transplantation, found here. The investigators found that in predicting antibody mediated rejection (AMR), donor-derived cell-free DNA (dd-cfDNA) testing with the Prospera Kidney test was superior to the current standard of care, donor-specific antibody (DSA) testing.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.